张奇,张瑞岩,张建盛,胡健,杨震坤,倪钧,张宪,沈卫峰

• 1: 上海交通大学医学院附属瑞金医院心内科
• 2:上海交通大学医学院附属瑞金医院心内科
• 3:上海交通大学医学院附属瑞金医院心内科
• 4:上海交通大学医学院附属瑞金医院心内科

摘要(Abstract)：

目的评估国产西罗莫司药物洗脱冠状动脉(冠脉)支架在冠心病患者中应用的安全性及1年临床随访结果,并与同期应用进口药物洗脱支架(Cypher和Taxus)比较。方法与结果2003年5月至2004年6月,共计673例经冠脉造影证实的冠心病患者接受药物洗脱支架治疗,其中接受国产西罗莫司药物洗脱支架(Firebird,上海微创公司)224例,进口西罗莫司药物洗脱支架(Cypher,美国强生公司)246例,进口紫杉醇药物洗脱支架(Taxus,美国波士顿公司)203例。各组基础临床情况及造影特征均相似,尽管Firebird组患者平均每例置入支架数目较多且支架总长度较长,但其住院总费用仍显著低于其他两组。术后1年临床随访严重心脏不良事件(包括心源性死亡、非致命性心肌梗死和靶血管再次血运重建)发生率在Firebird组为9·0%、Cypher组为8·4%、Taxus组为11·2%,相互比较差异无统计学意义。造影证实Firebird组2例(0·9%)、Cypher组2例(0·9%)和Taxus组3例(1·6%)发生支架内血栓形成。结论国产西罗莫司药物洗脱冠脉支架治疗冠心病安全,其1年临床疗效与进口西罗莫司及紫杉醇药物洗脱冠脉支架相似。

关键词(KeyWords)： 冠状动脉疾病;支架;西罗莫司

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张奇,张瑞岩,张建盛,胡健,杨震坤,倪钧,张宪,沈卫峰

参考文献(References)：

• [1]Homes DR,Leon MB,Moses JW,et al.Analysis of1-year clinical outcomes in the SIRIUS trial.A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation,2004,109:634-640.
• [2]Lemos PA,Serruys PW,van Domburg RT,et al.Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantationin the“real world”:the Rapamycin-Eluting Stent Evaluated At RotterdamCardiology Hospital(RESEARCH)registry.Circulation,2004,109:190-195.
• [3]Stone GW,Ellis SG,Cox DA,et al.Apolymer-based,paclitaxel-eluting stent in patients with coronary artery disease.NEngl J Med,2004,350:221-231.
• [4]Stone GW,Ellis SG,Cox DA,et al.One-year clinical results with the slow-release,polymer-based,paclitaxel-eluting TAXUS stent.The TAXUS-IVTrial.Circulation,2004,109:1942-1947.
• [5]Shen Y,Zhang Q,Shen WF et al.Early and short-term clinical outcome of Cypher drug-eluting coronary stenting.Shanghai Medicine,2003,26:168-170.
• [6]Zhang Q.Shen WF.Zhang JS et al.Early and short-termclinical outcome of ACS MULTI-LINK PENTAcoronary stent implantation.Interventional Radiology,2002,11:419-420.
• [7]Smith SC,Dove JT,Jacobs AK,et al.ACC/AHA guidelines forpercutaneous coronary intervention(revised of the1993PTCA guidelines).A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to revise the1993guidelines for percutaneous transluminal coronary angioplasty).J Am Coll Cardiol,2001,37:2239i-2239lxvi.
• [8]Moses JW,Leon MB,Popma JJ,et al.SIRIUS Investigators.Sirolimus-eluting stents versus standardstentsin patients withstenosis in a native coronary artery.NEngl J Med,2003,349:1315-1323.
• [9]Simonton CA,Brodie BR,Wilson BH.Drug-eluting stents for emerging treatment strategies in complex lesions.Rev Cardiovasc Med,2005,6:s38-s47.
• [10]Shafiq N,Malhotra S,Pandhi P,et al.A meta-analysis of clinical trials of paclitaxel-and sirolimus-eluting stents in patients with obstructive coronary artery disease.Br J Clin Pharmacol,2005,59:94-101.
• [11]Ong AT,Serruys PW,Aoki J,et al.The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population:one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital(T-RESEARCH)registry.J AmColl Cardiol,2005,45:1135-1141.
• [12]Stone GW,Ellis SG,Cox DA,et al.Apolymer-based,paclitaxel-eluting stent in patients with coronary artery disease.NEngl J Med,2004,350:221-231.
• [13]Morena R,Fernandez C,Hernandez R,et al.Drug-eluting stent thrombosis:results froma pooled analysis including10randomized studies.J AmColl Cardiol,2005,45:954-959.
• [14]Iakovou I,Schmidt T,Bonizzoni E,et al.Incidence,predictors,and outcome of thrombosis after successful implantationof drug-eluting stents.JAMA,2005,293:2126-2130.